Focused On-demand Library for Protein phosphatase 1 regulatory subunit 7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q15435

UPID:

PP1R7_HUMAN

Alternative names:

Protein phosphatase 1 regulatory subunit 22

Alternative UPACC:

Q15435; B4DFD4; B5MCY6; Q9UQE5; Q9UQE6; Q9Y6K4

Background:

Protein phosphatase 1 regulatory subunit 7, also known as Protein phosphatase 1 regulatory subunit 22, plays a crucial role as a regulatory subunit of protein phosphatase 1. This enzyme is pivotal in modulating cell division, signal transduction pathways, and muscle contractility among other cellular processes. Its regulatory capacity ensures the proper functioning of cellular mechanisms by dephosphorylating various key proteins.

Therapeutic significance:

Understanding the role of Protein phosphatase 1 regulatory subunit 7 could open doors to potential therapeutic strategies. Its central role in numerous cellular processes makes it a potential target for therapeutic intervention in diseases where these pathways are dysregulated.